| |
COMPOSITION
Each chewable tablet contains 100 mg of iron
as Ferric hydroxide polymaltose plus 350mcg of folic acid. |
| |
PROPERTIES
AND ACTION
FEROSE-F
chewable tablets for the treatment of iron and folic acid deficiencies
of all origins during pregnancy and lactation period. The folic acid
content corresponds to the recommendation of the WHO. Iron polymaltose,
the active iron ingredient of FEROSE-F chewable tablets is essentially
non-ionic, therefore, it has the following properties unlike ionised
iron salt preparations :
– It does not give rise to irritation of the intestinal mucosa and
does not stain the teeth.
– It has palatable, non metallic taste (chocolate flavour).
– It has excellent tolerance. FEROSE-F chewable tablets can be taken
with meals as appropriate to the patient, with any beverage or medicaments.
|
| |
INDICATIONS
Prevention and treatment of iron and folic acid
deficiencies of all origins during pregnancy and lactation period.
Dosage and Administration : In normal cases 1 tablet daily. Tablets
may be chewed or swallowed. In order to replenish the iron depots,
it is recommended to continue the treatment for a further month after
normalization of the blood values. |
| |
DOSAGE
AND ADMINISTRATION
In normal cases 1 tablet daily. Tablets may
be chewed or swallowed. In order to replenish the iron depots, it
is recommended to continue the treatment for a further month after
normalization of the blood values. |
| |
CONTRA-INDICATIONS
– Overloading of iron in the organism (haemochromatosis,
chronic haemolysis).
– Disturbances in iron utilization (lead anemia, sidero-achrestic
anemia), thalassaemia.
– Megaloblastic anemia due to vitamin B12 deficiency. |
| |
PRECAUTIONS
As with all oral iron preparations, a dark colouration
of the stool may occur which is without clinical significance. |
| |
UNDESIRABLE
EFFECTS
Occasionally GI irritation, pressure in the
epigastric region, nausea, constipation or diarrhoea may occur. Allergic
reactions have been reported rarely with folic acid. |
| |
PRESENTATIONS
FEROSE-F available in tablet formulation. |
